Barclays’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-9,800
| Closed | -$74K | – | 5529 |
|
|
2021
Q4 | $74K | Hold |
9,800
| – | – | ﹤0.01% | 3789 |
|
|
2021
Q3 | $88K | Hold |
9,800
| – | – | ﹤0.01% | 3958 |
|
|
2021
Q2 | $117K | Hold |
9,800
| – | – | ﹤0.01% | 3791 |
|
|
2021
Q1 | $123K | Sell |
9,800
-11,900
| -55% | -$160K | ﹤0.01% | 3915 |
|
|
2020
Q4 | $339K | Hold |
21,700
| – | – | ﹤0.01% | 3481 |
|
|
2020
Q3 | $205K | Hold |
21,700
| – | – | ﹤0.01% | 3827 |
|
|
2020
Q2 | $194K | Sell |
21,700
-33,800
| -61% | -$314K | ﹤0.01% | 4090 |
|
|
2020
Q1 | $354K | Buy |
55,500
+2,700
| +5% | +$20K | ﹤0.01% | 3856 |
|
|
2019
Q4 | $442K | Sell |
52,800
-8,600
| -14% | -$79.1K | ﹤0.01% | 4403 |
|
|
2019
Q3 | $556K | Buy |
61,400
+11,100
| +22% | +$125K | ﹤0.01% | 4159 |
|
|
2019
Q2 | $542K | Sell |
50,300
-15,000
| -23% | -$160K | ﹤0.01% | 4248 |
|
|
2019
Q1 | $623K | Sell |
65,300
-44,900
| -41% | -$459K | ﹤0.01% | 3910 |
|
|
2018
Q4 | $1.26M | Sell |
110,200
-8,300
| -7% | -$103K | ﹤0.01% | 2880 |
|
|
2018
Q3 | $2.01M | Buy |
118,500
+68,900
| +139% | +$1.05M | ﹤0.01% | 2878 |
|
|
2018
Q2 | $704K | Sell |
49,600
-29,100
| -37% | -$483K | ﹤0.01% | 3622 |
|
|
2018
Q1 | $1.5M | Buy |
78,700
+6,300
| +9% | +$135K | ﹤0.01% | 2765 |
|
|
2017
Q4 | $1.19M | Sell |
72,400
-20,000
| -22% | -$298K | ﹤0.01% | 2951 |
|
|
2017
Q3 | $1.39M | Sell |
92,400
-27,600
| -23% | -$305K | ﹤0.01% | 2694 |
|
|
2017
Q2 | $1.06M | Buy |
120,000
+75,900
| +172% | +$487K | ﹤0.01% | 2840 |
|
|
2017
Q1 | $229K | Sell |
44,100
-20,100
| -31% | -$80.6K | ﹤0.01% | 4175 |
|
|
2016
Q4 | $196K | Buy |
64,200
+32,900
| +105% | +$120K | ﹤0.01% | 4227 |
|
|
2016
Q3 | $145K | Buy |
31,300
+26,300
| +526% | +$134K | ﹤0.01% | 4227 |
|
|
2016
Q2 | $29K | Sell |
5,000
-27,100
| -84% | -$173K | ﹤0.01% | 5118 |
|
|
2016
Q1 | $193K | Sell |
32,100
-61,500
| -66% | -$369K | ﹤0.01% | 3875 |
|
|
2015
Q4 | $842K | Sell |
93,600
-6,500
| -6% | -$50.1K | ﹤0.01% | 2765 |
|
|
2015
Q3 | $501K | Sell |
100,100
-28,900
| -22% | -$238K | ﹤0.01% | 3339 |
|
|
2015
Q2 | $1.42M | Buy |
129,000
+26,600
| +26% | +$343K | ﹤0.01% | 2552 |
|
|
2015
Q1 | $1.54M | Buy |
102,400
+44,300
| +76% | +$685K | ﹤0.01% | 2571 |
|
|
2014
Q4 | $872K | Buy |
58,100
+31,200
| +116% | +$379K | ﹤0.01% | 3333 |
|
|
2014
Q3 | $269K | Sell |
26,900
-6,200
| -19% | -$81K | ﹤0.01% | 4479 |
|
|
2014
Q2 | $497K | Sell |
33,100
-309,900
| -90% | -$4.46M | ﹤0.01% | 3982 |
|
|
2014
Q1 | $6.17M | Buy |
343,000
+258,600
| +306% | +$4.98M | 0.01% | 1544 |
|
|
2013
Q4 | $1.1M | Buy |
84,400
+25,300
| +43% | +$291K | ﹤0.01% | 3303 |
|
|
2013
Q3 | $591K | Buy |
59,100
+22,700
| +62% | +$225K | ﹤0.01% | 3923 |
|
|
2013
Q2 | $284K | Buy |
+36,400
| New | +$318K | ﹤0.01% | 4834 |
|
Other funds holding SGMO
AC
VCM
VFT
Barclays's SGMO Position: Q1 2026 in Review
Barclays held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5385.
Barclays first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.28M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.
- Barclays held 1 share of SANGAMO THERAPEUTICS INC worth $0 as of Q1 2026.
- Barclays left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
- SANGAMO THERAPEUTICS INC made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5385 holding.
- Barclays first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
- Barclays's SANGAMO THERAPEUTICS INC position peaked at $5.28M in Q4 2020.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.